Building a Better Future for Medical Innovation
Q1: Why did you found TBM?
In 2016, we saw a striking gap in the market. China already possessed an incredible pool of engineering talent, a robust manufacturing base, and a massive clinical volumes, but the domestic medical device industry was largely focused on producing generic, copycat products. Original innovation is very rare.
We founded TBM to bridge that gap. We saw an opportunity to leverage those strengths to build a very efficient platform that transforms ideas into breakthroughs in medical technology. We didn't just want to make devices; we wanted to redefine how medical innovation happens and ensure that this innovation benefits patients around the world.
Q2: Please introduce your team and its key strengths.
Building original medical devices is a marathon, not a sprint. In China, professionals with genuine experience in ground-up R&D are incredibly rare. The team we've assembled are true pioneers—they've spent the last decade navigating a steep learning curve to master the art of original innovation in China.
Today, TBM is a 110-person team, with over a third of us dedicated entirely to R&D. We've recruited the brightest minds from the world's top universities. What truly sets them apart, though, isn't just their pedigree—it's their mindset. We've nurtured a culture that's curious, respectful of clinical science, and daring enough to explore uncharted territory. Every one of our engineers is driven by our mission, which is to ensure that our technology ultimately serves patients.
Q3: What makes TBM different from others in medical device innovation?
What sets us apart is that we've 'industrialized' the innovation process. We've moved away from the traditional, fragmented R&D model toward a high-efficiency, end-to-end platform.
Our Multi-Project R&D System is designed for robust risk mitigation and operational efficiency. We verify critical failure points step by step all the time to minimize single project risk. Simultaneously, we run multiple projects in parallel to maximize our team's productivity.
We developed our own ERP system, called Synes, for agile R&D management. It allows us to take a product from the first sketch all the way through to mass production. We also have a super exciting AI knowledge engine called Orca, it is tailored for complex medical scenarios. We've been training Orca since 2022, and aim to achieve automatic invention by the end of this year.
When you combine these in house tools with our rapid prototyping capabilities, we can develop innovative devices at such a high speed and at such a low cost that simply can't be matched.
I would say that we shouldn't be called a Chinese company. We are a global facilitator. We invite clinical experts from around the world to try plugging into our system to turn their boldest ideas into real-world medical solutions."
